Shanghai Shyndec Pharmaceutical Co Ltd600420
Mentioned
Impact on stocks 1
Others▲ · 1 stocks
Shanghai Shyndec Pharmaceutical Co LtdTheme Impact 1
Off-coverage companies
Related news
▲4
NRx Pharma rises as FDA completes initial review of ketamine product
Shares of NRx Pharmaceuticals rose after the FDA completed an initial review of its marketing application for a preservative-free ketamine product without identifying any major drug-related deficiencies. The regulator did not require new clinical or drug-related findings to prove safety and efficacy, but it classified a question about the luer lock tip of the medication vial as a major deficiency. Following a clarification meeting on August 6, NRx Pharma cited a substantially de-risked path to approval, noting that three ANDA-approved products on the market use the same luer-lock vial. CEO Jonathan Javitt said the company is encouraged by the FDA's commitment to review the remaining information in the shortest possible cycle.
▲10impact 4
Eli Lilly to acquire AtaiBeckley for $2.8 billion
Eli Lilly is acquiring psychedelic drug developer AtaiBeckley for $2.8 billion. The deal, which could be valued at up to $3.8 billion, marks a significant move into psychedelic-based mental health treatments. Mizuho Americas healthcare equity strategist Jared Holz noted that large-cap pharma is increasingly embracing alternative therapies, citing J&J's ketamine-based product annualizing nearly $2 billion. Holz expects 2025 to be a historic year for biotech M&A, with over 30 transactions north of a billion dollars.
2
AtaiBeckley Joins Russell 2000 and 3000 Indices, Canaccord Raises Price Target to $17
AtaiBeckley N.V. will be added to the Russell 2000 and Russell 3000 indices effective June 29, a move the company notes is significant given over $12 trillion in assets benchmarked to Russell indexes. Canaccord Genuity subsequently raised its price target on the stock from $15 to $17 on July 7, implying more than 227% upside, while reiterating a Buy rating. The revision followed completion of dosing in the Phase 2 Elumina trial of VLS-01 for treatment-resistant depression, with the company targeting Phase 3 development for major depressive disorder and potential expansion into generalized anxiety disorder. AtaiBeckley is a clinical-stage biopharmaceutical company focused on mental health therapies, with a pipeline that includes BPL-003 in Phase 2 for treatment-resistant depression and alcohol addiction, and RL-007 for cognitive decline from schizophrenia.